Download PDF Additional Analyses from Phase 2 Trial of Tivozanib and Phase 1 AV-299 Data to be Presented CAMBRIDGE, Mass., May 20, 2010 (BUSINESS WIRE) –AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO), a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced that data from the company’s tivozanib and AV-299 (SCH 900105) programs will be
Category: Press Release
AVEO Reports First Quarter 2010 Financial Results
Download PDF Significant Progress in Development of Lead Product Candidate Tivozanib; 2010 Financial Guidance Provided CAMBRIDGE, Mass., Apr 29, 2010 (BUSINESS WIRE) –AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO), a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced financial results for the quarter ended March 31, 2010, provided an update on progress towards
AVEO Pharmaceuticals, Inc. Announces Timing for First Quarter 2010 Financial Results, Webcast and Conference Call
Download PDF CAMBRIDGE, Mass., Apr 22, 2010 (BUSINESS WIRE) –AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO), a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced that financial results for the company’s first quarter ended March 31, 2010 will be released before the market opens on Thursday, April 29, 2010. The management team of
AVEO Pharmaceuticals’ Selective Anti-Notch1 Monoclonal Antibody Exhibits Potent Notch1 Inhibitory Activity
Download PDF Data Presented at AACR 101st Annual Meeting 2010; Confirm Potential Utility of AVEO’s Antibody Pipeline CAMBRIDGE, Mass., Apr 21, 2010 (BUSINESS WIRE) –AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO), a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced preclinical data which demonstrate that its Notch1-specific monoclonal antibody is a highly potent inhibitor
AVEO Pharmaceuticals Receives Milestone Payment from Biogen Idec under Licensing Agreement for ErbB3 Antibody Program
Download PDF Milestone Achieved Through Selection of First ErbB3 Antibody Development Candidate CAMBRIDGE, Mass., Apr 14, 2010 (BUSINESS WIRE) –AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO), a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced it has received a $5 million milestone payment from Biogen Idec International GmbH, a subsidiary of Biogen Idec, Inc.
Data from AVEO Pharmaceuticals’ Translational Research Platform and Novel Antibody Pipeline to be Presented at AACR 101st Annual Meeting 2010
Download PDF CAMBRIDGE, Mass., Apr 13, 2010 (BUSINESS WIRE) –AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO), a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced that preclinical data from its translational research platform and antibody pipeline will be presented during six poster sessions at the American Association for Cancer Research (AACR) 101st Annual Meeting
AVEO Pharmaceuticals, Inc. Announces Exercise of Over-Allotment Option for Recent Initial Public Offering
Download PDF CAMBRIDGE, Mass., April 1, 2010 –(BUSINESS WIRE)–AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO – News), a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced that the underwriters of its recently completed initial public offering of common stock have exercised their option to purchase an additional 968,539 shares of common stock to
AVEO Pharmaceuticals, Inc. Completes Initial Public Offering
Download PDF CAMBRIDGE, Mass., Mar 18, 2010 (BUSINESS WIRE) — AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO), a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced the completion of its initial public offering of 9,000,000 shares of its common stock. All shares were sold at an initial public offering price of $9.00 per
AVEO Pharmaceuticals, Inc. Announces Pricing of Its Initial Public Offering
Download PDF CAMBRIDGE, Mass., Mar 11, 2010 (BUSINESS WIRE) — AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO), a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced the pricing of its initial public offering of 9,000,000 shares of its common stock at $9.00 per share, before underwriting discounts and commissions. All of the common
AVEO Initiates Enrollment in Phase 3 Clinical Trial Evaluating Tivozanib in Advanced Renal Cell Cancer
Download PDF CAMBRIDGE, Mass., February 22, 2010 – AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced it has initiated enrollment in a global Phase 3 clinical trial for its oral, triple VEGF receptor inhibitor, tivozanib, in advanced renal cell cancer (RCC). This Phase 3 clinical trial, named